RRx-001 protects against cisplatin-induced toxicities

RRx-001 protects against cisplatin-induced toxicities J Cancer Res Clin Oncol (2017) 143:1671–1677 DOI 10.1007/s00432-017-2416-4 ORIGINAL ARTICLE – CANCER RESEARCH 1 3 3 4 Bryan Oronsky · Tony R. Reid · Christopher Larson · Corey A. Carter · 4 5 2 Christina E. Brzezniak · Arnold Oronsky · Pedro Cabrales Received: 10 March 2017 / Accepted: 30 March 2017 / Published online: 17 April 2017 © Springer-Verlag Berlin Heidelberg 2017 Abstract spreads were prepared from whole bone marrow cells as Purpose RRx-001, a minimally toxic tumor-associated markers of clastogenicity. macrophage and neutrophil-repolarizing agent, is under Results RRx-001 pretreatment significantly decreased investigation in Phase II clinical trials as a sensitizer/resen- (P < 0.05) the blood urea nitrogen and creatinine levels. sitizer to cisplatin and carboplatin. On the basis of anecdo- A statistically significant ( P < 0.05) reduction in the mean tal clinical observations of improved platinum tolerability total chromosome aberration frequency per metaphase in following a priming period with RRx-001 as well as pre- the RRx-001 and cisplatin group compared to the cisplatin- clinical studies that have previously demonstrated radiopro- only group was observed. tection of intestinal stem cells and cardioprotection from Conclusions This study is the first to demonstrate that doxorubicin, the in vivo http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Cancer Research and Clinical Oncology Springer Journals
Loading next page...
 
/lp/springer_journal/rrx-001-protects-against-cisplatin-induced-toxicities-4y3dLqCv5l
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Oncology; Cancer Research; Internal Medicine; Hematology
ISSN
0171-5216
eISSN
1432-1335
D.O.I.
10.1007/s00432-017-2416-4
Publisher site
See Article on Publisher Site

Abstract

J Cancer Res Clin Oncol (2017) 143:1671–1677 DOI 10.1007/s00432-017-2416-4 ORIGINAL ARTICLE – CANCER RESEARCH 1 3 3 4 Bryan Oronsky · Tony R. Reid · Christopher Larson · Corey A. Carter · 4 5 2 Christina E. Brzezniak · Arnold Oronsky · Pedro Cabrales Received: 10 March 2017 / Accepted: 30 March 2017 / Published online: 17 April 2017 © Springer-Verlag Berlin Heidelberg 2017 Abstract spreads were prepared from whole bone marrow cells as Purpose RRx-001, a minimally toxic tumor-associated markers of clastogenicity. macrophage and neutrophil-repolarizing agent, is under Results RRx-001 pretreatment significantly decreased investigation in Phase II clinical trials as a sensitizer/resen- (P < 0.05) the blood urea nitrogen and creatinine levels. sitizer to cisplatin and carboplatin. On the basis of anecdo- A statistically significant ( P < 0.05) reduction in the mean tal clinical observations of improved platinum tolerability total chromosome aberration frequency per metaphase in following a priming period with RRx-001 as well as pre- the RRx-001 and cisplatin group compared to the cisplatin- clinical studies that have previously demonstrated radiopro- only group was observed. tection of intestinal stem cells and cardioprotection from Conclusions This study is the first to demonstrate that doxorubicin, the in vivo

Journal

Journal of Cancer Research and Clinical OncologySpringer Journals

Published: Apr 17, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off